LV11279B - Pharmaceutical formulations of nerve growth factor - Google Patents

Pharmaceutical formulations of nerve growth factor Download PDF

Info

Publication number: LV11279B
Authority: LV; Latvia
Prior art keywords: ngf; formulation; formulations; composition; growth factor
Prior art date: 1993-08-20

Application number

LVP-96-48A

Other languages

English (en)

Latvian (lv)

Other versions

LV11279A (lv

Inventor

Victoria M Knepp

Deborah M Lidgate

Richard Maskiewicz

Leo Gu

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-20

Filing date

1996-02-19

Publication date

1996-10-20

1996-02-19 Application filed by Syntex Inc filed Critical Syntex Inc

1996-06-20 Publication of LV11279A publication Critical patent/LV11279A/xx

1996-10-20 Publication of LV11279B publication Critical patent/LV11279B/en

Links

108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 13
102000015336 Nerve Growth Factor Human genes 0.000 title claims abstract description 13
229940053128 nerve growth factor Drugs 0.000 title claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 title claims description 12
239000000872 buffer Substances 0.000 claims abstract description 39
238000004108 freeze drying Methods 0.000 claims abstract description 22
235000000346 sugar Nutrition 0.000 claims abstract description 19
239000000203 mixture Substances 0.000 claims description 141
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
150000003839 salts Chemical class 0.000 claims description 29
108091006905 Human Serum Albumin Proteins 0.000 claims description 23
102000008100 Human Serum Albumin Human genes 0.000 claims description 23
239000000243 solution Substances 0.000 claims description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
210000005036 nerve Anatomy 0.000 claims description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 12
229930006000 Sucrose Natural products 0.000 claims description 12
239000005720 sucrose Substances 0.000 claims description 12
238000001802 infusion Methods 0.000 claims description 10
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
229930195725 Mannitol Natural products 0.000 claims description 9
239000000594 mannitol Substances 0.000 claims description 9
235000010355 mannitol Nutrition 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 9
239000011780 sodium chloride Substances 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
239000007979 citrate buffer Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000000945 filler Substances 0.000 claims 3
230000002490 cerebral effect Effects 0.000 claims 1
239000013011 aqueous formulation Substances 0.000 abstract description 26
150000008163 sugars Chemical class 0.000 abstract description 11
238000009472 formulation Methods 0.000 description 117
238000004007 reversed phase HPLC Methods 0.000 description 29
108090000623 proteins and genes Proteins 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 16
238000004166 bioassay Methods 0.000 description 15
230000000694 effects Effects 0.000 description 13
238000000034 method Methods 0.000 description 12
-1 polyethylene Polymers 0.000 description 11
238000002965 ELISA Methods 0.000 description 9
238000003860 storage Methods 0.000 description 8
230000007423 decrease Effects 0.000 description 7
230000007774 longterm Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
102000046917 human NGF Human genes 0.000 description 6
230000036515 potency Effects 0.000 description 6
239000004698 Polyethylene Substances 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
239000011521 glass Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
229920000573 polyethylene Polymers 0.000 description 5
238000001179 sorption measurement Methods 0.000 description 5
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
238000007710 freezing Methods 0.000 description 4
230000008014 freezing Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
206010012289 Dementia Diseases 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
239000013078 crystal Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
230000005496 eutectics Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000000185 intracerebroventricular administration Methods 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
230000006764 neuronal dysfunction Effects 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
108091008604 NGF receptors Proteins 0.000 description 2
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 2
210000002932 cholinergic neuron Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
230000009477 glass transition Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000012931 lyophilized formulation Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001993 poloxamer 188 Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000000274 adsorptive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
229960002504 capsaicin Drugs 0.000 description 1
235000017663 capsaicin Nutrition 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000005308 flint glass Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
150000002840 non-reducing disaccharides Chemical class 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
229920006298 saran Polymers 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
210000001913 submandibular gland Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Psychology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LVP-96-48A 1993-08-20 1996-02-19 Pharmaceutical formulations of nerve growth factor LV11279B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/109,798 US6277828B1 (en)	1993-08-20	1993-08-20	Pharmaceutical formulations of nerve growth factor
PCT/US1994/009245 WO1995005845A1 (en)	1993-08-20	1994-08-16	Pharmaceutical formulations of nerve growth factor

Publications (2)

Publication Number	Publication Date
LV11279A LV11279A (lv)	1996-06-20
LV11279B true LV11279B (en)	1996-10-20

Family

ID=22329623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-96-48A LV11279B (en)	1993-08-20	1996-02-19	Pharmaceutical formulations of nerve growth factor

Country Status (31)

Country	Link
US (2)	US6277828B1 (ja)
EP (1)	EP0721343B1 (ja)
JP (2)	JP4592830B2 (ja)
KR (1)	KR100341193B1 (ja)
CN (1)	CN1163265C (ja)
AT (1)	ATE226085T1 (ja)
AU (1)	AU677699B2 (ja)
BG (1)	BG62951B1 (ja)
BR (1)	BR9407278A (ja)
CA (1)	CA2169834C (ja)
CZ (1)	CZ292422B6 (ja)
DE (1)	DE69431562T2 (ja)
DK (1)	DK0721343T3 (ja)
ES (1)	ES2181723T3 (ja)
FI (1)	FI113241B (ja)
HU (1)	HU228152B1 (ja)
IL (3)	IL124941A (ja)
LT (1)	LT4051B (ja)
LV (1)	LV11279B (ja)
NO (1)	NO317627B1 (ja)
NZ (1)	NZ271873A (ja)
PL (1)	PL176387B1 (ja)
PT (1)	PT721343E (ja)
RO (1)	RO114742B1 (ja)
RU (1)	RU2126265C1 (ja)
SI (1)	SI9420048B (ja)
SK (1)	SK284064B6 (ja)
TW (1)	TW427905B (ja)
UA (1)	UA43348C2 (ja)
WO (1)	WO1995005845A1 (ja)
ZA (1)	ZA946333B (ja)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
US6444201B1 (en) *	1995-05-12	2002-09-03	The Rockefeller University	Treatment of alzheimer disease by modulation of synapsins
US6964947B1 (en)	1995-11-07	2005-11-15	Genentech, Inc.	Stabilizing formulation for NGF
US6090781A (en) *	1996-11-06	2000-07-18	Genentech, Inc.	Stabilizing formulation for NGF
DK0862452T3 (da) *	1995-11-07	2004-04-05	Genentech Inc	Stabiliserende formulering af NGF
CA2256333A1 (en) *	1996-05-29	1997-12-04	Victor Bronshtein	Long-term shelf preservation by vitrification
CN1059597C (zh) *	1996-08-08	2000-12-20	陈素兰	神经损伤修复制剂
ES2278411T3 (es) *	1997-05-01	2007-08-01	Protechtion Unlimited, Inc.	Factor de crecimiento nervioso como adyuvante de vacuna.
US6313089B1 (en)	1997-08-20	2001-11-06	Duke University	Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
WO1999016460A2 (en) *	1997-09-30	1999-04-08	Duke University	Apolipoprotein e/growth factor complexes and methods of use
US6979442B1 (en)	1998-08-17	2005-12-27	Pfizer Inc.	Stabilized protein compositions
AU2002351756A1 (en) *	2001-12-21	2003-07-15	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
KR20040065278A (ko) *	2001-12-21	2004-07-21	노보 노르디스크 에이/에스	변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AR038568A1 (es) *	2002-02-20	2005-01-19	Hoffmann La Roche	Anticuerpos anti-a beta y su uso
US20040009918A1 (en) *	2002-05-03	2004-01-15	Hanne Nedergaard	Stabilised solid compositions of modified factor VII
PT1517698E (pt)	2002-06-21	2014-11-19	Novo Nordisk Healthcare Ag	Composições sólidas estabilizadas de polipéptidos do fator viia
RU2005132164A (ru) *	2003-03-18	2006-06-10	Ново Нордиск Хелт Кэр Аг (Ch)	Жидкие, водные фармацевтические композиции полипептидов фактора vii
US7897734B2 (en) *	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
KR20060015574A (ko) *	2003-05-23	2006-02-17	노보 노르디스크 헬스 케어 악티엔게젤샤프트	용액 중 단백질 안정화
CN1318087C (zh) *	2003-06-06	2007-05-30	北京三诺佳邑生物技术有限责任公司	去白蛋白神经生长因子制剂
WO2004112828A1 (en) *	2003-06-25	2004-12-29	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
EP1644030B1 (en) *	2003-07-01	2009-10-28	Novo Nordisk Health Care AG	Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ES2574581T3 (es) *	2003-08-14	2016-06-20	Novo Nordisk Health Care Ag	Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
DE10355251A1 (de) *	2003-11-26	2005-06-23	Merck Patent Gmbh	Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
RU2373953C2 (ru) *	2003-12-19	2009-11-27	Ново Нордиск Хелс Кеа Аг	Стабилизированная композиция, содержащая полипептид фактора vii
US8168222B2 (en)	2004-09-07	2012-05-01	Board Of Regents Of The University Of Nebraska	Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) *	2004-09-07	2011-09-13	Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center	Amphiphilic polymer-protein conjugates and methods of use thereof
CA2659562A1 (en) *	2006-08-14	2008-02-21	Eisai R&D Management Co., Ltd.	Stable lyophilized preparation
EP2081645B8 (en) *	2006-11-08	2013-07-10	P· MIND Co., Ltd	Apparatus for accelerating production of neurotrophic factor
EP1958618A1 (de)	2007-02-15	2008-08-20	Octapharma AG	Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
CA2738274A1 (fr) *	2008-09-26	2010-04-01	Adocia	Complexe constitue d'un polysaccharide et d'une hpb
CN102232932B (zh) *	2010-04-27	2013-06-05	重庆莱美药业股份有限公司	果胶-阿霉素轭合物的冻干制剂及制备方法
CA2832260C (en)	2011-04-07	2021-06-22	Neovacs	Method for treating ifnalpha related conditions
US20150005236A1 (en) *	2012-02-08	2015-01-01	Institut National De La Recherche Agronomique	Use of beta-nerve growth factor for inducing ovulation in mammals
US20180110833A1 (en) *	2015-04-21	2018-04-26	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Nerve growth factor composition and powder injection
CN107660149B (zh) *	2015-04-21	2021-04-27	舒泰神（北京）生物制药股份有限公司	一种神经生长因子组合物及注射粉剂
ES2893239T3 (es) *	2015-04-21	2022-02-08	Staidson Beijing Biopharmaceuticals Co Ltd	Composición de factor de crecimiento nervioso y polvo de inyección
US9868828B2 (en) *	2015-06-23	2018-01-16	Amolifescience Co., Ltd.	Defined three-dimensional microenvironment for stem cell
JPWO2017164349A1 (ja)	2016-03-25	2019-02-07	アステラス製薬株式会社	ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物
KR102783452B1 (ko) *	2016-06-01	2025-03-19	세르비에 아이피 유케이 리미티드	폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
CN109260147B (zh) *	2018-10-15	2019-09-13	珠海亿胜生物制药有限公司	一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en)	2020-08-14	2023-09-26	Albcura Corporation	Albumin compositions and methods of producing and using same
IL302317A (en)	2020-10-28	2023-06-01	Dompe Farm Spa	Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4497431A1 (en) *	2023-07-27	2025-01-29	Dompé farmaceutici S.p.A.	Pharmaceutical formulation comprising nerve growth factor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0193917A3 (en) *	1985-03-06	1987-09-23	American Cyanamid Company	Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
NZ222413A (en)	1986-11-05	1991-06-25	Ethicon Inc	Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
NZ226170A (en) *	1987-09-18	1990-07-26	Ethicon Inc	Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) *	1988-03-18	1990-05-24	Fidia Farmaceutici	Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en)	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
JPH0418031A (ja) *	1989-02-16	1992-01-22	Hiroshi Saito	損傷治癒促進剤
US5169834A (en) *	1990-11-30	1992-12-08	American Cyanamid Company	Compositions and method for reducing vial breakage during lyophilization
AU1442592A (en) *	1991-02-20	1992-09-15	Nova Pharmaceutical Corporation	Controlled release microparticulate delivery system for proteins
JP3283288B2 (ja) *	1991-03-08	2002-05-20	電気化学工業株式会社	生理活性ペプチド製剤
JP2818834B2 (ja) *	1991-08-12	1998-10-30	大塚製薬株式会社	ＩＬ−１α安定化医薬製剤

1993
- 1993-08-20 US US08/109,798 patent/US6277828B1/en not_active Expired - Lifetime
1994
- 1994-08-16 SK SK183-96A patent/SK284064B6/sk not_active IP Right Cessation
- 1994-08-16 DK DK94925903T patent/DK0721343T3/da active
- 1994-08-16 PT PT94925903T patent/PT721343E/pt unknown
- 1994-08-16 WO PCT/US1994/009245 patent/WO1995005845A1/en not_active Ceased
- 1994-08-16 CA CA002169834A patent/CA2169834C/en not_active Expired - Lifetime
- 1994-08-16 RO RO96-00301A patent/RO114742B1/ro unknown
- 1994-08-16 CZ CZ1996424A patent/CZ292422B6/cs not_active IP Right Cessation
- 1994-08-16 RU RU96105951A patent/RU2126265C1/ru active
- 1994-08-16 UA UA96020622A patent/UA43348C2/uk unknown
- 1994-08-16 AU AU75668/94A patent/AU677699B2/en not_active Expired
- 1994-08-16 AT AT94925903T patent/ATE226085T1/de active
- 1994-08-16 EP EP94925903A patent/EP0721343B1/en not_active Expired - Lifetime
- 1994-08-16 ES ES94925903T patent/ES2181723T3/es not_active Expired - Lifetime
- 1994-08-16 KR KR1020017005635A patent/KR100341193B1/ko not_active Expired - Lifetime
- 1994-08-16 PL PL94313084A patent/PL176387B1/pl unknown
- 1994-08-16 JP JP50764495A patent/JP4592830B2/ja not_active Expired - Lifetime
- 1994-08-16 SI SI9420048A patent/SI9420048B/sl unknown
- 1994-08-16 HU HU9600371A patent/HU228152B1/hu unknown
- 1994-08-16 CN CNB94193148XA patent/CN1163265C/zh not_active Expired - Lifetime
- 1994-08-16 BR BR9407278A patent/BR9407278A/pt not_active Application Discontinuation
- 1994-08-16 DE DE69431562T patent/DE69431562T2/de not_active Expired - Lifetime
- 1994-08-16 NZ NZ271873A patent/NZ271873A/en not_active IP Right Cessation
- 1994-08-19 ZA ZA946333A patent/ZA946333B/xx unknown
- 1994-08-19 IL IL124941A patent/IL124941A/en not_active IP Right Cessation
- 1994-08-19 IL IL11072594A patent/IL110725A/en not_active IP Right Cessation
- 1994-08-30 TW TW083107604A patent/TW427905B/zh not_active IP Right Cessation
1996
- 1996-02-19 LV LVP-96-48A patent/LV11279B/en unknown
- 1996-02-19 NO NO19960651A patent/NO317627B1/no not_active IP Right Cessation
- 1996-02-19 BG BG100371A patent/BG62951B1/bg unknown
- 1996-02-19 LT LT96-011A patent/LT4051B/lt not_active IP Right Cessation
- 1996-02-19 FI FI960750A patent/FI113241B/fi not_active IP Right Cessation
1998
- 1998-06-16 IL IL12494198A patent/IL124941A0/xx active IP Right Grant
2001
- 2001-02-20 US US09/789,855 patent/US7074763B2/en not_active Expired - Fee Related
2007
- 2007-08-08 JP JP2007206876A patent/JP2007314572A/ja active Pending

Also Published As

Publication number	Publication date
KR100341193B1 (ko)	2002-06-21
PT721343E (pt)	2003-01-31
CZ42496A3 (en)	1996-05-15
PL313084A1 (en)	1996-05-27
HK1012990A1 (en)	1999-08-13
LT96011A (en)	1996-07-25
IL124941A (en)	2006-12-10
HU228152B1 (en)	2012-12-28
RU2126265C1 (ru)	1999-02-20
SK284064B6 (sk)	2004-09-08
PL176387B1 (pl)	1999-05-31
FI113241B (fi)	2004-03-31
SI9420048B (sl)	2003-12-31
EP0721343B1 (en)	2002-10-16
EP0721343A1 (en)	1996-07-17
JP4592830B2 (ja)	2010-12-08
DE69431562T2 (de)	2003-06-18
NO960651D0 (no)	1996-02-19
UA43348C2 (uk)	2001-12-17
BR9407278A (pt)	1996-10-01
FI960750L (fi)	1996-02-20
RO114742B1 (ro)	1999-07-30
JP2007314572A (ja)	2007-12-06
BG100371A (bg)	1996-12-31
NO317627B1 (no)	2004-11-29
LT4051B (en)	1996-10-25
CA2169834A1 (en)	1995-03-02
CA2169834C (en)	2008-11-04
FI960750A0 (fi)	1996-02-19
SK18396A3 (en)	1996-10-02
NO960651L (no)	1996-02-19
US7074763B2 (en)	2006-07-11
LV11279A (lv)	1996-06-20
AU7566894A (en)	1995-03-21
CN1133012A (zh)	1996-10-09
CZ292422B6 (cs)	2003-09-17
ZA946333B (en)	1996-02-19
US6277828B1 (en)	2001-08-21
IL124941A0 (en)	1999-01-26
IL110725A (en)	2004-09-27
ES2181723T3 (es)	2003-03-01
BG62951B1 (bg)	2000-12-29
CN1163265C (zh)	2004-08-25
HUT74728A (en)	1997-02-28
HU9600371D0 (en)	1996-04-29
US20010007662A1 (en)	2001-07-12
ATE226085T1 (de)	2002-11-15
NZ271873A (en)	1996-10-28
AU677699B2 (en)	1997-05-01
DK0721343T3 (da)	2003-02-17
JPH10508000A (ja)	1998-08-04
IL110725A0 (en)	1994-11-11
WO1995005845A1 (en)	1995-03-02
DE69431562D1 (de)	2002-11-21
SI9420048A (en)	1996-10-31
TW427905B (en)	2001-04-01

Publication	Publication Date	Title
EP0721343B1 (en)	2002-10-16	Pharmaceutical formulations of nerve growth factor
FI120291B (fi)	2009-09-15	Lisäkilpirauhasen hormoniformulaation valmistusmenetelmä
US7163701B2 (en)	2007-01-16	Controlled release microencapsulated NGF formulation
Österberg et al.	1997	Development of a freeze-dried albumin-free formulation of recombinant factor VIII SQ
EP0410207B1 (en)	1997-01-22	Stabilization of highly purified proteins
JPH05331071A (ja)	1993-12-14	カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
CN120112314A (zh)	2025-06-06	抗her3抗体药物偶联物组合物及其医药用途
KR100310796B1 (ko)	2002-06-24	신경생육인자약학배합물
HK1012990B (en)	2003-03-28	Pharmaceutical formulations of nerve growth factor
JP3501471B2 (ja)	2004-03-02	カルシトニン類の安定化組成物および安定化法
EP1189600B1 (en)	2003-09-10	Grf-containing lyophilized pharmaceutical compositions
WO1995022342A1 (en)	1995-08-24	Pharmaceutical formulations of ciliary neurotrophic factor
AU5184401A (en)	2001-12-06	Controlled release microencapsulated ngf formulation
JP2009149684A (ja)	2009-07-09	アミリン作動薬ペプチド用製剤
HK1050142A1 (en)	2003-06-13	Glp-2 formulations